Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene Lab's ROE % for the quarter that ended in Mar. 2026 was -26.05%. BioNexus Gene Lab's PB Ratio for the quarter that ended in Mar. 2026 was 0.64.
BioNexus Gene Lab's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -40.70%.
BioNexus Gene Lab ROE % Adjusted to Book Value Related Terms
BioNexus Gene Lab ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab ROE % Adjusted to Book Value Chart
BGLC vs QGAI, VYST, GLGI: ROE % Adjusted to Book Value Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab ROE % Adjusted to Book Value vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -40.70% mean?
BioNexus Gene Lab (BGLC) has a ROE % Adjusted to Book Value of -40.70% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioNexus Gene Lab and its competitors.
Is BioNexus Gene Lab's ROE % Adjusted to Book Value too high?
BioNexus Gene Lab's current ROE % Adjusted to Book Value is -40.70%. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's ROE % Adjusted to Book Value compare to QGAI and VYST?
BioNexus Gene Lab's ROE % Adjusted to Book Value of -40.70% can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Chemicals company?
A good ROE % Adjusted to Book Value depends on the Chemicals industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current ROE % Adjusted to Book Value is -40.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current ROE % Adjusted to Book Value is -40.70%. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current ROE % Adjusted to Book Value is -40.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
ROE % Adjusted to Book Value: -40.70%
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
